UC Davis Medical Center has become the first hospital in Western U.S. to perform a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter.
Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.”
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Jeffrey A. Drebin, MD, PhD, has been named President-Elect of the American Surgical Association (ASA) for 2024.
The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.
Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction.
The Advanced Psychiatric Therapeutics Clinic offers esketamine and transcranial magnetic stimulation (TMS) for patients with treatment-resistant depression.
Two researchers from The University of Texas MD Anderson Cancer Center will be honored with Scientific Achievement Awards at the American Association for Cancer Research (AACR) Annual Meeting 2024 for accomplishments in clinical and translational research as well as outstanding leadership in oncology.
A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the molecular subgroups of RCC tumors to better understand how their makeup might affect treatment responses.
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
Padmanee Sharma, M.D., Ph.D., associate vice president of Immunobiology, professor of Genitourinary Medical Oncology and Immunology, and director of scientific programs for the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, has been elected to the 2024 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her work to establish and advance immune checkpoint therapies as effective treatments for patients with a variety of cancers.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer in the U.S., or 21.9%, participate in some form of clinical research.
Moffitt Cancer Center announced today a collaboration with NVIDIA, Oracle and Deloitte* on an initiative aimed at revolutionizing cancer care delivery through advanced artificial intelligence and machine learning technologies.
Staring at the sun can damage your eyes in less than a minute. An ophthalmologist explains how to protect your vision during the 2024 eclipse.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Benyi Li, MD, PhD, professor in the Department of Urology and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense to develop a short peptide-based therapy for prostate cancer patients.
Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital.
In a survey of more than 200 U.S. oncologists, vast majority indicate that oncologists should be able to explain how AI works to their patients. Respondents say AI developers, more than oncologists or hospitals, have responsibility for legal issues arising from AI use in cancer care.
Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
UC Davis Health received a $3 million grant to support research by the Black & Brown Collective. The group is studying gun violence that disproportionately impacts marginalized communities.
The American Society of Clinical Oncology (ASCO) recognized Janet L. Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as a recipient of an ASCO Special Award, the Society’s highest honor.
Many cancers can be prevented, and others can be detected early in their development, treated and cured.
Mariam F. Eskander, MD, MPH, surgical oncologist in the Gastrointestinal Oncology Program at Rutgers Institute of New Jersey, offers insight and tips for minority individuals navigating a cancer diagnosis and how we can all work together to mitigate cancer disparities.
Vignesh T. Packiam, MD, director of Clinical and Translational Research in Urologic Oncology and a urologic oncologist in the Urologic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center, shares about testicular cancer and what men should know.
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
Benjamin Medina, MD, thoracic surgeon in the Lung/Thoracic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, answers common questions about esophageal cancer during esophageal cancer awareness month.
A new study published in JAMA Neurology found human brains are getting bigger. The increased size may lead to a brain reserve, potentially reducing the risk of dementia.
For the fifth straight time, the American Nurses Credentialing Center (ANCC) has awarded Magnet® status to Dana-Farber Cancer Institute, recognizing excellence in nursing practice and patient care.
A new study of California firearm data identifies specific risk factors associated with a legally purchased gun that is later used in a crime.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Nirag Jhala, MD, as chief of the Division of Oncologic Pathology at New Jersey’s leading cancer program and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center.
MD Anderson's Institute for Data Science in Oncology today announced the appointment of its inaugural cohort of 33 IDSO Affiliates, who bring diverse expertise to advance the work of the institute and foster the data science ecosystem at MD Anderson.
Infectious diseases specialists call the medical field to be ready to deal with the impact of climate change on spreading diseases, such as malaria, Valley fever, E-coli and Lyme disease.
The UNM Comprehensive Center is expanding a program aimed at encouraging young people to explore research as a career field. In addition to a first-ever middle school component, the program is adding more opportunities for high school and undergraduates to get real world lab and research experience.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Taneal D. Carter, MS, MPA, Manager of Cancer Care Equity Program for NCCN, has been named one of 2024’s ‘40 Under 40’ by the National Minority Quality Forum (NMQF). Visit NCCN.org/equity for more information.
UC Davis health researchers evaluated California’s mental health crisis management and prevention programs. Their report identified gaps in the system and called for more sustainable programs and community collaborations to support people with mental illness.
20240208171546.png&width=400&height=400)
A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3/UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors.
Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).
Yale Cancer Center (YCC) and Smilow Cancer Hospital physicians and scientists will share new data for breakthrough and emerging cancer treatments as well as new discoveries in obesity, tobacco, evolution, and early onset cancers in early April at the American Association for Cancer Research (AACR) annual meeting.
Students who use both tobacco and cannabis (marijuana) have lower grades and miss more school than students who only use one product or don’t use either. Tobacco consumption among high school students, including vaping and e-cigarettes, is a concerning 12.6%.
Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute. In this new role, he will lead Dana-Farber's institutional research strategy with an initial focus on therapeutic discovery work.
A blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detected colorectal cancer in 83% of people confirmed to have the disease, according to a study published March 14 in the New England Journal of Medicine.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tengteng Wang, PhD, MSPH, MBBS, cancer epidemiologist in the Section of Cancer Epidemiology and Health Outcomes at Rutgers Cancer Institute of New Jersey, has received more than $700,000 from the National Cancer Institute (R00CA267557) to support her research on examining the association between reproductive factors, gut microbiome, and benign breast disease (BBD).
Our GI cancer specialists perform the newest and most effective practices for diagnosing and treating pre-cancerous and cancerous conditions involving the colon. Dr. Pat Gulhati breaks down colorectal cancer and the advancements at Rutgers Cancer Institute, New Jersey's only NCI-designated Comprehensive Cancer Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
